Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Depreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased

Daily Values

Others

Ratios

Atea Pharmaceuticals (AVIR) Capital Expenditures (2020 - 2022)

Atea Pharmaceuticals' Capital Expenditures history spans 2 years, with the latest figure at $20000.0 for Q3 2022.

Quarterly Capital Expenditures changed N/A to $20000.0 in Q3 2022 from the year-ago period, while the trailing twelve-month figure was $1.9 million through Dec 2022, changed N/A year-over-year, with the annual reading at $1.9 million for FY2022, 48475.0% up from the prior year.
Capital Expenditures came in at $20000.0 for Q3 2022, down from $1.2 million in the prior quarter.
In the past five years, Capital Expenditures ranged from a high of $1.2 million in Q2 2022 to a low of $5000.0 in Q4 2020.